InSite Vision Incorporated (OTCBB:INSV) today announced that Timothy
Ruane, Chief Executive Officer of InSite Vision, will present a company
update at 8:30 am ET at the Newsmakers in the Biotech Industry
Conference being held at the Millennium Broadway Hotel and Conference
Center in New York City on Friday, October 21, 2011.
Mr. Ruane will discuss InSite's pipeline of novel clinical-stage
ophthalmic therapeutics, including AzaSite Plus™ and DexaSite™
poised to begin a Phase 3 clinical study for the treatment of
blepharitis, and BromSite™ (formerly ISV-303) being developed
for pain and inflammation associated with cataract surgery. The
presentation will also be webcast and available on the Investor
Relations page of the company's website at www.insitevision.com.
The presentation will be archived for replay at the same address for a
period of 30 days.
About InSite Vision
InSite Vision is advancing new and superior ophthalmologic products for
unmet eye care needs. The company’s product portfolio utilizes InSite
Vision’s proven DuraSite® bioadhesive polymer core
technology, an innovative platform that extends the duration of drug
retention on the surface of the eye, thereby reducing frequency of
treatment and improving the efficacy of topically delivered drugs. The
DuraSite platform is currently leveraged in two commercial products for
the treatment of bacterial eye infections, AzaSite®
(azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck,
and Besivance® (besifloxacin ophthalmic suspension) 0.6%,
marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s
clinical-stage ophthalmic product pipeline includes AzaSite Plus™
(ISV-502) and DexaSite™ (ISV-305) for the treatment of eye
infections, BromSite™ (ISV-303) for pain and swelling
associated with ocular surgery, and ISV-101 for the treatment of dry eye
disease. For further information on InSite Vision, please visit www.insitevision.com.
AzaSite® and DuraSite® are registered trademarks
of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch & Lomb
Incorporated.
